Summary
This study provides a systematic evaluation of the bioavailability of cannabidiolic acid (CBDA) and nine other cannabinoids, combining validated UHPLC-based analytical methods with both cellular (Caco-2) and rodent in vivo models. The research investigates whether the complex phytochemical matrix of Cannabis sativa, sometimes described as the 'entourage effect', modulates cannabinoid absorption. The findings are expected to contribute pharmacokinetic evidence relevant to the formulation of cannabis-derived pharmaceutical and food-grade products.
UK applicability
Although conducted in the Czech Republic, the findings are highly relevant to the UK given growing regulatory interest in CBD and cannabinoid-based food supplements and medicines under MHRA and FSA oversight. The pharmacokinetic data on CBDA bioavailability could inform product formulation standards and labelling requirements in the UK market.
Key measures
Apparent permeability coefficients (Papp) from Caco-2 assays; plasma concentration and pharmacokinetic parameters (e.g. AUC, Cmax, Tmax) from mouse in vivo studies; UHPLC-MS/MS quantification of cannabinoids and matrix components
Outcomes reported
The study measured the absorption and bioavailability of ten cannabinoids (including both neutral forms and acid precursors) using Caco-2 cell monolayers and an inbred mouse model. It also assessed whether non-cannabinoid matrix components associated with the 'cannabis synergy' (entourage) effect influence bioavailability.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.